• Mednow (MNOW) has released its financial results for the period ending January 31, 2022
  • Q2 revenue increased by over 230 per cent quarter-over-quarter and more than 1,400 per cent year-over-year
  • Karim Nassar, CEO of Mednow sat down with Dave Jackson to discuss the results
  • Mednow is a healthcare technology company
  • Mednow Inc. (MNOW) opened trading at C$0.81 per share

Mednow (MNOW) has released its financial results for the period ending January 31st, 2022. 

Q2 revenue increased by over 230 per cent quarter-over-quarter and more than 1,400 per cent year-over-year.

Karim Nassar, CEO and Co-Founder of Mednow Inc. sat down with Dave Jackson to discuss the results.

“I am so fortunate to work with a gifted team of Mednow employees who have tirelessly committed their time and skills to build out Mednow’s vision of leading the digital health evolution, to redefine pharmacy’s role in holistic care.

Over the last quarter, we have continued to accelerate revenue, while enhancing our technology applications, growing our tuck-in acquisitions, and increasing our uniquely differentiated product offerings. We are thrilled to be able to service customers coast-to-coast by summer 2022, and we will now embark on a significant national marketing campaign.”

Mednow is a Canadian-based healthcare technology company. Mednow.ca provides virtual pharmacy and telemedicine services, as well as doctor home visits.

Mednow Inc. (MNOW) opened trading at C$0.81 per share. 

More From The Market Online

Avicanna launches 10% CBD (THC free) formula in Canada

Avicanna (TSX:AVCN) launches RHO Phyto Micro Drop 100, a 10 per cent CBD (THC free), proprietary oral formulation in Canada.

@ the Bell: Markets advance on mining and financial support

Canada's main stock index inched higher on Wednesday, tracking an uptick in precious metals prices, though a drop in oil prices capped gains.
The Market Online Video

Prospera Energy plots success with proven reserves, M&A plans

Prospera Energy (TSXV:PEI) CEO Samuel David discusses the company's latest news and the forecast for 2024 in an exclusive interview.